Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Urogen Pharma Ltd
(NQ:
URGN
)
13.73
-0.24 (-1.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Urogen Pharma Ltd
< Previous
1
2
3
4
5
6
7
Next >
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Ltd. (NASDAQ: URGN) Leading the Way in Friday Trading Based on Percentage Gain
July 28, 2023
Via
Investor Brand Network
Why Shares of UroGen Pharma Jumped Friday
July 28, 2023
The company released positive top-line results for two studies for a bladder cancer treatment.
Via
The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
July 28, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...
Via
Benzinga
Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session
July 28, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
UroGen Pharma Ltd. (NASDAQ: URGN) Near the Top of Equities by Percentage Gain on 7/27
July 27, 2023
Via
Investor Brand Network
Recap: UroGen Pharma Q1 Earnings
May 11, 2023
Via
Benzinga
UroGen Pharma Earnings Preview
March 15, 2023
Via
Benzinga
Why UroGen Pharma Stock Is Gaining Today?
July 27, 2023
UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients...
Via
Benzinga
UroGen Announces $120 Million Private Placement of Ordinary Shares
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
July 25, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
July 10, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
July 06, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
June 20, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
June 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments
May 11, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023
May 04, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For May 11, 2023
May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...
Via
Benzinga
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation
May 01, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis
April 30, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
April 25, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
March 16, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 16, 2023
March 16, 2023
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.
Via
Benzinga
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
March 09, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
March 01, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer
February 15, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
February 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.